Sorted By Test Name - Mayo Medical Laboratories

CMM
87277
CMVC8
88826
4-5 AU/mL (equivocal)
> or =6 AU/mL (positive)
A convalescent IgG antibody level of >6 AU/mL combined with a ratio of > or =2 in a paired sera
(seroconversion) IgG titer indicates recent infection. The presence of only IgG antibodies generally
indicates past infection with CMV.
Clinical References: 1. Kusne S, Shapiro R, Fung J: Prevention and treatment of cytomegalovirus
infection in organ transplant recipients. Transpl Infect Dis 1999;1(3):187-203 2. Rubin RH: Importance of
CMV in the transplant population. Transpl Infect Dis 1999;1(1):3-7
Cytomegalovirus (CMV) Antibodies, IgM, Serum
Clinical Information: Cytomegalovirus (CMV) is a significant cause of morbidity and mortality,
especially in organ transplant recipients and individuals with AIDS. (1,2) CMV is also responsible for
congenital disease of the newborn. The most common infections with CMV in immunocompromised
hosts result from reactivation of the virus (latent) from a previous infection, transmission of the virus from
a donor organ or blood product, or initial or primary contact with the virus in a seronegative patient.
Infection in immunologically normal patients can cause mononucleosis similar to that produced by
infection with Epstein-Barr virus (EBV).
Useful For: Diagnosis of primary, acute phase infection with cytomegalovirus (CMV), especially in
patients with infectious mononucleosis and pregnant women who, based on clinical signs or exposure,
may have primary CMV infection
Interpretation: Negative cytomegalovirus (CMV) IgM results suggest that an individual is not
experiencing a recent infection. However, a negative result does not rule out primary CMV infection. It
has been reported that CMV-specific IgM antibody was not detectable in 10% to 30% of cord blood sera
from infants demonstrating infection in the first week of life. In addition, up to 23% (3/13) of pregnant
women with primary CMV infection did not demonstrate detectable CMV IgM responses within 8 weeks
post-infection. In cases of primary infection where the time of seroconversion is not well defined as high
as 28% (10/36) of pregnant women did not demonstrate CMV IgM antibody. Positive CMV IgM results
indicate a recent infection (primary, reactivation, or reinfection). IgM antibody responses in secondary
(reactivation) CMV infections have been demonstrated in some CMV mononucleosis patients, in a few
pregnant women, and in renal and cardiac transplant patients. Levels of antibody may be lower in
transplant patients with secondary rather than primary infections.
Reference Values:
Negative (reported as positive or negative)
The presence of IgM class antibodies indicates recent infection.
Clinical References: 1. Kusne S, Shapiro R, Fung J: Prevention and treatment of cytomegalovirus
infection in organ transplant recipients. Transpl Infect Dis 1999;1(3):187-203 2. Rubin RH: Importance of
CMV in the transplant population. Transpl Infect Dis 1999;1(1):3-7 3.Lang D, Vornhagen R, Rothe M, et
al: Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus
antigens containing glycine homopolymers. Clin Diagn Lab Immunol 2001 July;8(4):747-756
Cytomegalovirus (CMV) CD8 T-Cell Immune Competence,
Quantitative Assessment by Flow Cytometry
Clinical Information: Cytomegalovirus (CMV), a double-stranded DNA virus, belongs to the
Herpesviridae family of viruses and is structurally similar to other herpes viruses. Although many human
strains of CMV exist, there is little genetic homology between human CMV and CMV of other species.
The reported seroprevalence rates of CMV range from 40% to 100% in the general population. In the
urban United States (US), the seroprevalence of CMV has been reported to be 60% to 70 %.(1) However,
data from Mayo's laboratory indicate that the seroprevalence in the midwestern US population is closer to
30% (unpublished observations). Once CMV infection occurs, the virus spreads hematogenously to
almost every organ. After acute infection, the virus enters a latent phase. Activation from this phase can
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 589